CBL-0137 is under clinical development by Incuron and currently in Phase II for Lymphoma. According to GlobalData, Phase II drugs for Lymphoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBL-0137’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBL-0137 overview
CBL-0137 (CBLC-137) is under development for the treatment of resistant or refractory advanced solid cancers, osteosarcoma, relapsed and refractory lymphoma, previously untreated CNS tumors and pediatric diffuse intrinsic pontine glioma. It is administered through oral, intraarterial, and intravenous routes. The drug candidate is a carbazole-derived compound. It is developed based on Curaxin technology.
It was also under development for the treatment of pancreatic ductal adenocarcinoma, melanoma (second line therapy), sarcoma (second line therapy), colon adenocarcinoma, renal cell carcinoma, human non-small cell lung cancer, mammary gland adenocarcinoma, pancreatic cancer, head and neck cancer, prostate cancer, melanoma, glioblastoma, neuroblastoma, glioblastoma multiforme (second line therapy), hematological malignancies like diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, Hodgkin lymphoma (B -cell Hodgkin lymphoma), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (all, acute lymphoblastic leukemia), acute myelocytic leukemia (aml, acute myeloblastic leukemia), multiple myeloma (Kahler disease), B -cell non-Hodgkin lymphoma and human African trypanosomiasis.
Incuron overview
Incuron is a biotechnology company developing anticancer therapies. Incuron is headquartered in Moscow, Russia.
For a complete picture of CBL-0137’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
